Previous Close | 25.79 |
Open | 25.72 |
Bid | 25.49 x 100 |
Ask | 25.94 x 100 |
Day's Range | 25.14 - 25.79 |
52 Week Range | 16.54 - 28.67 |
Volume | |
Avg. Volume | 67,874 |
Market Cap | 381.241M |
Beta (5Y Monthly) | 0.84 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.24 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.00 |
BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (“Options”) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, and (ii) restricted stock units (
Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed
Anika Therapeutics ( NASDAQ:ANIK ) First Quarter 2024 Results Key Financial Results Revenue: US$40.5m (up 6.9% from 1Q...